{"id":"placebo-matching-dapaglifolzin","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo control, this formulation contains no active pharmaceutical ingredient but is manufactured to match the appearance, taste, and physical properties of dapagliflozin tablets to maintain blinding in clinical trials. Dapagliflozin itself works by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, allowing filtered glucose to be excreted in urine rather than reabsorbed into the bloodstream.","oneSentence":"This is a placebo formulation designed to match dapagliflozin, an SGLT2 inhibitor that reduces blood glucose by blocking renal glucose reabsorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:01:09.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control for dapagliflozin clinical trials"}]},"trialDetails":[{"nctId":"NCT06054035","phase":"PHASE4","title":"SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-10-26","conditions":"Type2diabetes, PreDiabetes, Renal Failure","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo matching Dapaglifolzin","genericName":"Placebo matching Dapaglifolzin","companyName":"University Hospital Tuebingen","companyId":"university-hospital-tuebingen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation designed to match dapagliflozin, an SGLT2 inhibitor that reduces blood glucose by blocking renal glucose reabsorption. Used for Placebo control for dapagliflozin clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}